A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Inclusion Criteria:

   - Adult patients, >/= 18 years of age

   - Histologically or cytologically confirmed Stage III B or Stage IV squamous non-small
   cell lung cancer (NSCLC)

   - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

   - No prior chemotherapy for squamous NSCLC

   - Adequate tissue for central IHC assay of Met receptor, and EGFR testing if EGFR status
   is unknown

   - Radiographic evidence of disease

Exclusion Criteria:

   - Prior systemic treatment for Stage IIIB or IV squamous NSCLC

   - NSCLC with histology classified as adenocarcinoma, large cell, mixed adenosquamous, or
   NSCLC not otherwise specified (NOS)

   - Prior exposure to experimental treatment targeting either the HGF or Met pathway

   - Patients with tumors confirmed to have EGFR-activating mutations who are suitable for
   anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator

   - Uncontrolled brain metastases and treatment by neurosurgical resection or brain biopsy
   within 4 weeks prior to Day 1 of Cycle 1

   - History of another malignancy in the previous 3 years except for prior history of in
   situ cancer or basal or squamous cell skin cancer

   - Pregnant or lactating women

   - Uncontrolled diabetes

   - Impaired bone marrow, liver or renal function as defined by protocol

   - Significant history of cardiovascular disease

   - Positive for HIV infection